- Commercial agreement marks the first for Cognetivity's 'at home', non-clinical health monitoring technology
- Cognetivity tool to be offered to dacadoo's existing user base of major health and life insurance partners on a per-user subscription basis
VANCOUVER, Nov. 6, 2018 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (FWB: 1UB) (OTCQB: CGNSF) today announced that it has signed a commercial agreement with dacadoo, a fast-growing global provider of digital health platforms, to provide a first-of-its-kind cognitive assessment tool for dacadoo's client base of major life and health insurance providers.
The agreement covers the commercial relationship between Cognetivity and dacadoo and allows the companies to work together to make Cognetivity's advanced cognitive assessment platform available to dacadoo's corporate partners in health and life insurance on an ongoing, per-user, subscription basis.
By adding Cognetivity's 'at home' cognitive assessment tool to its digital health engagement platform, dacadoo has the opportunity to offer its existing and future life and health insurance clients a highly-unique and valuable new technology for monitoring cognitive health.
Cognetivity's CEO and Director, Dr. Sina Habibi, commented: "This agreement represents a significant opportunity for us to make our proprietary technology available to a mass user base within the new and rapidly-growing area of non-clinical health monitoring. Whether it be via our professional platform for early cognitive impairment diagnosis, which is in its final stages of clinical validation, or our at-home health monitoring tool being integrated with dacadoo, our key mission remains clearly focused on giving people control of their health and ensuring the best possible health outcomes for as many people as possible."
Peter Ohnemus, Founder, President and CEO of dacadoo, added: "We are very happy to partner with Cognetivity and provide our insurer customers with access to its impressive, AI-driven technologies in the space of cognitive monitoring."
According to a 2018 report by Transparency Market Research, the global digital health market was valued at approximately US$180 bn in 2016. Expanding at an expected CAGR of 13.40% from 2017, the market is projected to reach approximately US$535 bn by the end of 2025.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information please visit – www.cognetivity.com
About dacadoo AG
dacadoo is a globally active and an innovative business partner, which promotes digital transformation in healthcare. Their aim is to strengthen health and wellbeing through active engagement and artificial intelligence, and their comprehensive digital health engagement platform motivates its users with a playful approach to a healthy lifestyle and makes health individually measurable. The mobile dacadoo health engagement platform combines motivation techniques from behavioral science and online games, with social and collaborative features from social networks as well as personalized feedback. On the basis of scientifically founded "Health Scoring" and health coaching by the "Lifestyle Navigator", dacadoo offers leading digital solutions for companies in the healthcare sector as well as for corporate health promotion and wellness.
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd